Segui
Romain Seban
Romain Seban
Email verificata su curie.fr
Titolo
Citata da
Citata da
Anno
18F-FDG PET and CT scans detect new imaging patterns of response and progression in patients with Hodgkin lymphoma treated by anti–programmed death 1 immune checkpoint inhibitor
L Dercle, RD Seban, J Lazarovici, LH Schwartz, R Houot, S Ammari, ...
Journal of Nuclear Medicine 59 (1), 15-24, 2018
1212018
Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors
RD Seban, L Mezquita, A Berenbaum, L Dercle, A Botticella, ...
European journal of nuclear medicine and molecular imaging 47, 1147-1157, 2020
1132020
Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics
RD Seban, JS Nemer, A Marabelle, R Yeh, E Deutsch, S Ammari, ...
European journal of nuclear medicine and molecular imaging 46, 2298-2310, 2019
1032019
Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy
L Dercle, S Ammari, S Champiat, C Massard, C Ferté, L Taihi, RD Seban, ...
European journal of cancer 65, 33-42, 2016
652016
Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in …
E Lopci, RJ Hicks, A Dimitrakopoulou-Strauss, L Dercle, A Iravani, ...
European journal of nuclear medicine and molecular imaging 49 (7), 2323-2341, 2022
542022
Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4
RD Seban, A Moya-Plana, L Antonios, R Yeh, A Marabelle, E Deutsch, ...
European journal of nuclear medicine and molecular imaging 47, 2301-2312, 2020
532020
Early 18F-FDG PET/CT response predicts survival in relapsed or refractory Hodgkin lymphoma treated with nivolumab
A Chen, FZ Mokrane, LH Schwartz, F Morschhauser, A Stamatoullas, ...
Journal of Nuclear Medicine 61 (5), 649-654, 2020
412020
Fibroblast heterogeneity in solid tumors: From single cell analysis to whole-body imaging
A Peltier, RD Seban, I Buvat, FC Bidard, F Mechta-Grigoriou
Seminars in Cancer Biology 86, 262-272, 2022
362022
Association of the metabolic score using baseline FDG-PET/CT and dNLR with immunotherapy outcomes in advanced NSCLC patients treated with first-line pembrolizumab
RD Seban, JB Assié, E Giroux-Leprieur, MA Massiani, M Soussan, ...
Cancers 12 (8), 2234, 2020
342020
Performance of CT Compared with 18F-FDG PET in Predicting the Efficacy of Nivolumab in Relapsed or Refractory Hodgkin Lymphoma
FZ Mokrane, A Chen, LH Schwartz, F Morschhauser, A Stamatoullas, ...
Radiology 295 (3), 651-661, 2020
342020
Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma
L Dercle, S Ammari, RD Seban, LH Schwartz, R Houot, N Labaied, ...
European Journal of Cancer 91, 136-144, 2018
342018
Prognostic value of inflammatory response biomarkers using peripheral blood and [18F]-FDG PET/CT in advanced NSCLC patients treated with first-line chemo-or immunotherapy
RD Seban, JB Assié, E Giroux-Leprieur, MA Massiani, G Bonardel, ...
Lung Cancer 159, 45-55, 2021
302021
FDG-PET biomarkers associated with long-term benefit from first-line immunotherapy in patients with advanced non-small cell lung cancer
RD Seban, JB Assie, E Giroux-Leprieur, MA Massiani, M Soussan, ...
Annals of Nuclear Medicine 34, 968-974, 2020
292020
Diagnostic and prognostic value of 18F-FDG PET, CT, and MRI in perineural spread of head and neck malignancies
L Dercle, D Hartl, L Rozenblum-Beddok, FZ Mokrane, RD Seban, R Yeh, ...
European Radiology 28, 1761-1770, 2018
252018
Redifferentiating Effect of Larotrectinib in NTRK-Rearranged Advanced Radioactive-Iodine Refractory Thyroid Cancer
L Groussin, H Theodon, L Bessiene, L Bricaire, F Bonnet-Serrano, ...
Thyroid 32 (5), 594-598, 2022
222022
Outcomes of patients with cancer and sarcoid-like granulomatosis associated with immune checkpoint inhibitors: A case–control study
C Cabanié, S Ammari, S Hans, C Pobel, A Laparra, FX Danlos, ...
European Journal of Cancer 156, 46-59, 2021
182021
Total metabolic tumor volume and spleen metabolism on baseline [18F]-FDG PET/CT as independent prognostic biomarkers of recurrence in resected breast cancer
RD Seban, R Rouzier, A Latouche, N Deleval, JM Guinebretiere, I Buvat, ...
European Journal of Nuclear Medicine and Molecular Imaging 48, 3560-3570, 2021
172021
Increased bone marrow SUVmax on 18F-FDG PET is associated with higher pelvic treatment failure in patients with cervical cancer treated by chemoradiotherapy and brachytherapy
RD Seban, C Robert, L Dercle, R Yeh, A Dunant, S Reuze, A Schernberg, ...
Oncoimmunology 8 (5), e1574197, 2019
172019
Emerging and evolving concepts in cancer immunotherapy imaging
L Dercle, S Sun, RD Seban, A Mekki, R Sun, L Tselikas, S Hans, ...
Radiology 306 (1), 32-46, 2023
152023
Immune response visualized in vivo by [18F]-FDG PET/CT after COVID-19 vaccine
RD Seban, L Champion, N Deleval, C Richard, C Provost
Diagnostics 11 (4), 676, 2021
142021
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20